1. Home
  2. TRUP vs GLPG Comparison

TRUP vs GLPG Comparison

Compare TRUP & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Trupanion Inc.

TRUP

Trupanion Inc.

HOLD

Current Price

$36.41

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Galapagos NV

GLPG

Galapagos NV

HOLD

Current Price

$31.80

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRUP
GLPG
Founded
2000
1999
Country
United States
Belgium
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.1B
IPO Year
2014
2005

Fundamental Metrics

Financial Performance
Metric
TRUP
GLPG
Price
$36.41
$31.80
Analyst Decision
Buy
Hold
Analyst Count
3
4
Target Price
$56.33
$31.33
AVG Volume (30 Days)
427.8K
111.0K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,399,759,000.00
$336,643,201.00
Revenue This Year
$14.02
$3.61
Revenue Next Year
$9.35
N/A
P/E Ratio
$100.91
N/A
Revenue Growth
12.50
10.31
52 Week Low
$31.00
$22.36
52 Week High
$57.89
$37.78

Technical Indicators

Market Signals
Indicator
TRUP
GLPG
Relative Strength Index (RSI) 44.27 51.01
Support Level $33.68 $31.41
Resistance Level $38.70 $32.75
Average True Range (ATR) 1.33 0.51
MACD 0.36 0.16
Stochastic Oscillator 54.79 51.23

Price Performance

Historical Comparison
TRUP
GLPG

About TRUP Trupanion Inc.

Trupanion Inc is a specialty insurance products provider in the United States. Its core business is the sale of insurance products tailor-made for pets, especially cats and dogs. It operates in two business segments: The subscription business segment generates revenue majorly from subscription fees related to the Company's direct-to-consumer products and Other business segment is comprised of revenue from other product offerings that generally have a business-to-business relationship and a different margin profile than subscription business segment, including revenue from writing policies on behalf of third parties and revenue from other products and software solutions.

About GLPG Galapagos NV

Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.

Share on Social Networks: